Cargando…

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

BACKGROUND: Alemtuzumab is a highly effective therapy for relapsing-remitting multiple sclerosis (RRMS), and immune thrombocytopenia (ITP) has been identified as a risk. OBJECTIVE: To examine ITP incidence, treatment, and outcomes during the clinical development of alemtuzumab for RRMS and discuss p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuker, Adam, Bass, Ann D, Nadj, Congor, Agius, Mark A, Steingo, Brian, Selmaj, Krzysztof W, Thoits, Timothy, Guerreiro, Alexandre, Van Wijmeersch, Bart, Ziemssen, Tjalf, Meuth, Sven G, LaGanke, Christopher C, Thangavelu, Karthinathan, Rodriguez, Claudio E, Baker, Darren P, Margolin, David H, Jannsens, Ann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950888/ https://www.ncbi.nlm.nih.gov/pubmed/30785358 http://dx.doi.org/10.1177/1352458518816612

Ejemplares similares

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
por: Dayan, Colin M., et al.
Publicado: (2023)

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
por: Van Wijmeersch, Bart, et al.
Publicado: (2019)

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings
por: Barclay, Krista, et al.
Publicado: (2019)

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years
por: Horáková, Dana, et al.
Publicado: (2020)

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
por: Coles, Alasdair J, et al.
Publicado: (2021)

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
por: Coles, Alasdair J., et al.
Publicado: (2021)

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings
por: Coles, Alasdair J., et al.
Publicado: (2017)

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
por: Havrdova, Eva, et al.
Publicado: (2017)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223
por: Steingo, Brian, et al.
Publicado: (2020)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
por: Thomas, Katja, et al.
Publicado: (2016)

Influence of Cognitive and Motor Abilities on the Level of Current Functioning in People with Multiple Sclerosis
por: Slavkovic, Sanela, et al.
Publicado: (2019)

Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis
por: Akgün, Katja, et al.
Publicado: (2020)

Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab
por: Jung, Chul Won, et al.
Publicado: (2016)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus
por: Lambert, Catherine, et al.
Publicado: (2018)

Long-term efficacy of alemtuzumab in polymyositis
por: Ruck, Tobias, et al.
Publicado: (2015)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
por: Wiendl, Heinz, et al.
Publicado: (2019)

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies
por: Comi, Giancarlo, et al.
Publicado: (2019)

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
por: Arnold, Douglas L., et al.
Publicado: (2016)

Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management
por: Decallonne, Brigitte, et al.
Publicado: (2018)

The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
por: Alroughani, Raed, et al.
Publicado: (2020)

Immune thrombocytopenia: vaccination does not equal causation
por: Pishko, Allyson, et al.
Publicado: (2022)

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study
por: Singer, Barry A, et al.
Publicado: (2023)

Heparin-induced thrombocytopenia: An illustrated review
por: May, Jori, et al.
Publicado: (2023)

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
por: Möhn, Nora, et al.
Publicado: (2019)

Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis
por: Graves, Jennifer, et al.
Publicado: (2013)

Transitioning patients with immune thrombocytopenia to second‐line therapy: Challenges and best practices
por: Cuker, Adam
Publicado: (2018)

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
por: Phelps, Richard, et al.
Publicado: (2019)

Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study
por: Freedman, Mark S, et al.
Publicado: (2018)

Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern
por: Cuker, Adam, et al.
Publicado: (2021)

Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study
por: Singer, Barry, et al.
Publicado: (2012)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

Case Report: Adult Still’s Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient
por: Krämer, Julia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m6iro200ft396bp85cqad99hko